Floatz logo

Prior-Hsct Donor-Derived Cd7 Car T-Cell

T-cell Malignancies

Beijing GoBroad HospitalCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the T-cell Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
New York Medical College
Phase 3BBB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 3BB
CYCLOSPORIN A
Medical College of Wisconsin
Phase 3B
Umbilical Cord Blood Mononuclear Cells
Masonic Cancer Center, University of Minnesota
Phase 2B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 26 →

Same molecule, other indications

Prior-Hsct Donor-Derived Cd7 Car T-Cell is also rated in:

T-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
45 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →